1020MO AdvanTIG-203: Phase II randomized, multicenter study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell death-ligand 1 (PD-L1) positivity

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 34; p. S621
Main Authors Wang, F., Lin, C-Y., Sun, J-M., Lu, C-H., Zhu, X., Chen, Z., Kim, I-H., Pan, Y., Zhang, J., Tougeron, D., Kim, S-B., Van Cutsem, E., Abdrashitov, R., Ge, R., Sun, J., Zhou, J., Xu, R-H.
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.10.2023
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2023.09.2159